Navigation Links
Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
Date:2/25/2013

SAN FRANCISCO, Feb. 25, 2013 /PRNewswire/ -- Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in a Phase 2 study of its lead investigational drug candidate for the prevention of post-surgical pain, AYX1.

The 90-patient, placebo-controlled study will evaluate the safety and efficacy of a single administration of AYX1 given prior to unilateral total knee arthroplasty (TKA) to reduce acute pain and to prevent the transition to persistent pain. The study will follow patients for 42 days, with a primary endpoint of pain with walking. Secondary and exploratory endpoints will include pain at rest, pain with knee range of motion, rate and extent of functional recovery, opioid consumption and safety assessments. Further details of the study can be found at www.clinicaltrials.gov

"While many widely used pain therapies require repeat dosing for symptom amelioration, or require heavy dosing with associated side-effects to treat pain with movement, a single administration of AYX1 has the potential to block the development of pain before it begins," said Donald Manning , M.D., Ph.D., chief medical officer of Adynxx. "This study will evaluate AYX1's ability to reduce acute pain and prevent persistent pain, especially pain associated with movement, enabling patients to begin rehabilitation and resume other activities earlier."

Dennis Podlesak , chairman of the Adynxx board of directors, added, "AYX1 is a novel new treatment option that has the potential to transform how patients suffering from post-surgical pain are treated, and to provide patients and physicians with an innovative and advantageous approach to pain management.  The clinical and preclinical results to date
'/>"/>

SOURCE Adynxx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study
2. Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1
3. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
4. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
5. First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
6. The Emirate of Abu Dhabi Becomes First to Have JCI Accredited Long-Term Care Facility Outside of USA
7. Specialty Pharmacy Association of America (SPAARx) - Enrollment Exceeds 1,000 Members in First Two Weeks since Launch
8. Research Units Across the World go for the First 3 Tesla, Cryogen Free MRI Bench Top Scanner
9. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
10. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
11. Smt. Sheila Dikshit Unveils South Asias First PET SUITE at Indraprastha Apollo Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of novel bile acid ... biliary cirrhosis, today announced that Mark Pruzanski ... present at the Deutsche Bank Securities 38th Annual Health ... Wednesday, May 29, 2013 at 4:10 p.m. ET. ...
(Date:5/23/2013)... , May 23, 2013  Omeros Corporation ... its Investigational New Drug Application (IND) to evaluate ... the U.S. Food and Drug Administration (FDA). OMS824 ... in areas of the brain linked to a ... Huntington,s disease and schizophrenia. OMS824 has shown promising ...
(Date:5/23/2013)... 23, 2013  MedVantx, Inc., the company that has ... announced today the Company has completed a major expansion ... pharmaceutical products and the upgrade of its systems to ... in its specialty home delivery pharmacy in ... pharmaceutical manufacturers, physicians, health systems and payors novel distribution ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3
... N.D., Dec. 16, 2011  Crystal3 Labs, Inc., a cGMP contract ... today that it has been acquired by an individual ... of the transaction were not disclosed. The company also ... Founded in 2007, Global Pharma Analytics provides ...
... ( Medical Device and Diagnostic Industry , UBM ... latest news , information, and in-depth analysis, announced a series of ... of medical device design.  "We,re taking a close ... industry," stated Brian Buntz, Editor for MD+DI. "To some, the focus ...
Cached Medicine Technology:Crystal3 Labs Acquired by Individual Investor, Vithalbhai Dhaduk, M.D. 2MD+DI, the Global MedTech Industry Authority, Highlights the Human Element in Medical Device Design: Designing the Devices Surgeons Want and Pushing the Boundaries of Innovation 2MD+DI, the Global MedTech Industry Authority, Highlights the Human Element in Medical Device Design: Designing the Devices Surgeons Want and Pushing the Boundaries of Innovation 3
(Date:5/23/2013)... 2013 The sodium theory ... and B. Katz in the early 1950s, after their ... of sodium and potassium ions in nerve functions ... acquisition techniques have known amazing developments. In The Sodium ... give an account of the latest developments in the ...
(Date:5/23/2013)... 2013 Orange County film studio and visual ... light leaks for Apple's Final Cut Pro X ... you no longer have to worry about matching up the ... shot," Said Christina Austin, CEO of Pixel Film Studios, "You ... natural look." , ProLeak from Pixel Film Studios allows users ...
(Date:5/23/2013)... Dr. Damon Huffman of Huffman Family Dentistry is ... a revolutionary new treatment method with the Laser Assisted New ... suffer from periodontal disease, and many of them do not ... is hoping that LANAP will encourage many of those people ... , Periodontal disease can cause gums to recede and even ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Funeral Financials ... Memorial Day to the EOD Memorial Foundation ... be the greatest victims from the war. , ... originated in 1941 before the U.S. was even at ... Forces are identified with the Explosive Ordnance Disposal Badge. ...
(Date:5/23/2013)... Lake City, UT (PRWEB) May 23, 2013 ... 3.0 , a comprehensive radiology learning environment for ... with prebuilt lessons and assessments, transforms the learning ... comprehensive radiology curriculum. , “Until RADPrimer ... is second to none,” comments Dr. B.J. Manaster, ...
Breaking Medicine News(10 mins):Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 3Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2Health News:Humble, TX Dentist, Dr. Damon Huffman Now Offers Laser Periodontal Disease Treatment to Gum Disease Patients 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 3Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2
... African swine fever, a devastating pig disease that could ... Organisation said Friday. ,"This is a dramatic ... the Rome-based FAO, noting that the highly contagious viral ... since 1990." ,Armenia, Azerbaidjan and Russia "should ...
... survivors can halve the risk of dying from the disease ... of their weight, suggests a longitudinal study from the ... (UCSD). ,Published in the Journal of Clinical Oncology, ... of a combination of both healthy diet and physical activity ...
... aging in fruit flies with a new technique that shows ... triumph for pests, scientists have found out how to make ... may still have something for humans. As reported online in ... slow down aging holds implications for humans prolonged existence and ...
... diagnosed cancer in men. More than 218,000 men will be ... 27,000 will die . June is Prostate Cancer Awareness Month, ... about the ways men can keep their prostates healthy and ... caused by benign prostatic enlargement affect the vast majority of ...
... department of Health today confirmed the death of a Madison County ... case in 2007 and it seems to be much earlier ... due to the virus. ,Four Mississippians have contracted West ... according to the Health Department and the Centers for Disease Control ...
... gave birth to twins at a hospital in London, where she ... ,The 47-year-old and her husband of ten years, Paul Berges, ... only next month. ,Predicting the early arrival of twins, ... and that she and Berges are really thrilled about it. ...
Cached Medicine News:Health News:Healthy Diet, Exercise can Halve the Risk of Mortality in Breast Cancer Survivors 2Health News:Super Fruit Fly may Harbor Hope for Human Longevity 2Health News:Tips to Maintain a Healthy Prostate 2Health News:First Case of West Nile Virus Death in Madison County 2
... nonsurgical, physician-administered treatment that can temporarily smooth ... brows in people from 18 to 65 ... treatment of its type approved by the ... Cosmetic is a purified protein produced by ...
... is a non-animal stabilized hyaluronic acid-based ... filler to enter the U.S. market. ... moderate to severe facial wrinkles and ... is injected just under the skins ...
... SCULPTRA™ is an injectable ... poly-L-lactic acid, a biocompatible, biodegradable, ... family. SCULPTRA is reconstituted prior ... of Sterile Water for Injection, ...
... is clinically proven to reduce the appearance ... cream-gel formula combines Retinol, the purest form ... Caffeine. It works deep within skin's surface ... bumpy appearance. Fast absorbing, it has a ...
Medicine Products: